+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market 2019-2023 - Product Image

Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market 2019-2023

  • ID: 4791000
  • Report
  • June 2019
  • Region: Global
  • 130 pages
  • TechNavio

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Amgen Inc.
  • AstraZeneca Plc
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • MORE
Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market: About this market

The epidermal growth factor receptor (EGFR) is a protein-coding gene. It is found in high levels on cancer cells and is known to be responsible for the uncontrolled cell growth Inhibiting or blocking the growth of EGFR can stop the growth of cancer cells for long durations of time. The epidermal growth factor receptor inhibitors market analysis considers the revenue based on indications such as lung cancer, colorectal cancer, breast cancer, and others. Our analysis also finds the sales of the epidermal growth factor receptor inhibitors in North America, Europe, Asia, and ROW. In 2018, lung cancer had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the substantial prevalence of the disease will play a vital role in the lung cancer segment to maintain its market position. Also, our global epidermal growth factor receptor inhibitors market report looks at factors such as the substantial prevalence of major cancer indications, increasing awareness campaigns, and research funding. However, the high treatment costs, high preference for alternative therapies, and patent cliff may hamper the growth of the epidermal growth factor receptor inhibitors industry over the forecast period.

Global epidermal growth factor receptor inhibitors market: Overview

Strong prevalence of major cancer indications

The prevalence of various types of cancers has increased at a significant rate in recent years, owing to increasing geriatric population and changing lifestyle. The market is witnessing the vast unmet need for novel therapies for the treatment of cancer indications. This is creating huge opportunities for vendors to conduct studies on drugs such as EGFR inhibitors for the treatment of cancer. Thus, the substantial prevalence of major cancer indications will lead to the growth of the global EGFR inhibitors market at a CAGR of almost 9% during the forecast period.

New research areas

EGFR inhibitors are considered to be highly effective for the treatment of various types of cancer indications, which is encouraging researchers to study its use in the treatment of inflammatory and monogenic diseases. Hence, the new research areas of EGFR inhibitors are identified as a critical trend that will have a positive impact on the growth of the EGFR inhibitors market during the forecast period.

Competitive Landscape

With the presence of a few significant players, the global epidermal growth factor receptor inhibitors market is concentrated. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading epidermal growth factor receptor inhibitors manufacturers, that include Amgen Inc., AstraZeneca Plc, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., and Novartis AG.

Also, the epidermal growth factor receptor inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all future growth opportunities.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen Inc.
  • AstraZeneca Plc
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY INDICATION
  • Market segmentation by indication
  • Comparison by indication
  • Lung cancer - Market size and forecast 2018-2023
  • Colorectal cancer - Market size and forecast 2018-2023
  • Breast cancer - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by indication
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Amgen Inc.
  • AstraZeneca Plc
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Indication - Market share 2018-2023 (%)
Exhibit 18: Comparison by indication
Exhibit 19: Lung cancer - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Lung cancer - Year-over-year growth 2019-2023 (%)
Exhibit 21: Colorectal cancer - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Colorectal cancer - Year-over-year growth 2019-2023 (%)
Exhibit 23: Breast cancer - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Breast cancer - Year-over-year growth 2019-2023 (%)
Exhibit 25: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Estimated number of new cancer cases and deaths in the US - 2019
Exhibit 27: Others - Year-over-year growth 2019-2023 (%)
Exhibit 28: Market opportunity by indication
Exhibit 29: Customer landscape
Exhibit 30: Market share by geography 2018-2023 (%)
Exhibit 31: Geographic comparison
Exhibit 32: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: North America - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in North America
Exhibit 35: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Europe
Exhibit 38: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in Asia
Exhibit 41: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 42: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 43: Top 3 countries in ROW
Exhibit 44: Key leading countries
Exhibit 45: Market opportunity
Exhibit 46: Estimated new cancer cases and deaths in US 2019
Exhibit 47: Organizations conducting awareness campaigns
Exhibit 48: Impact of drivers and challenges
Exhibit 49: Global EGFR inhibitors market: pipeline
Exhibit 50: Vendor landscape
Exhibit 51: Landscape disruption
Exhibit 52: Vendors covered
Exhibit 53: Vendor classification
Exhibit 54: Market positioning of vendors
Exhibit 55: Amgen Inc. - Vendor overview
Exhibit 56: Amgen Inc. - Business segments
Exhibit 57: Amgen Inc. - Organizational developments
Exhibit 58: Amgen Inc. - Geographic focus
Exhibit 59: Amgen Inc. - Key offerings
Exhibit 60: Amgen Inc. - Key customers
Exhibit 61: AstraZeneca Plc - Vendor overview
Exhibit 62: AstraZeneca Plc - Business segments
Exhibit 63: AstraZeneca Plc - Organizational developments
Exhibit 64: AstraZeneca Plc - Geographic focus
Exhibit 65: AstraZeneca Plc - Key offerings
Exhibit 66: AstraZeneca Plc - Key customers
Exhibit 67: Eli Lilly and Co. - Vendor overview
Exhibit 68: Eli Lilly and Co. - Business segments
Exhibit 69: Eli Lilly and Co. - Organizational developments
Exhibit 70: Eli Lilly and Co. - Geographic focus
Exhibit 71: Eli Lilly and Co. - Segment focus
Exhibit 72: Eli Lilly and Co. - Key offerings
Exhibit 73: Eli Lilly and Co. - Key customers
Exhibit 74: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 75: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 76: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 77: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 78: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 79: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 80: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 81: Novartis AG - Vendor overview
Exhibit 82: Novartis AG - Business segments
Exhibit 83: Novartis AG - Organizational developments
Exhibit 84: Novartis AG - Geographic focus
Exhibit 85: Novartis AG - Segment focus
Exhibit 86: Novartis AG - Key offerings
Exhibit 87: Novartis AG - Key customers
Exhibit 88: Validation techniques employed for market sizing
Exhibit 89: Definition of market positioning of vendors
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen Inc.
  • AstraZeneca Plc
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • MORE
The following companies are recognised as the key players in the global epidermal growth factor receptor inhibitors market: Amgen Inc., AstraZeneca Plc, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., and Novartis AG.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the new research areas.”

According to the report, one of the major drivers for this market is the strong prevalence of significant cancer indications.

Further, the report states that one of the major factors hindering the growth of this market is the high preference for alternative therapies.

The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
  • Amgen Inc.
  • AstraZeneca Plc
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll